Please login to the form below

Not currently logged in
Email:
Password:

anti-PD-1

This page shows the latest anti-PD-1 news and features for those working in and with pharma, biotech and healthcare.

FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer

FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer

However, treating the disease from a ‘different angle’, Opdivo can target and block the activity of PD-1, a protein that prevents T cells from recognising and attacking inflamed tissues and ... It’s a significant win for BMS, which is chasing rival

Latest news

  • Keytruda is first I-O drug cleared for melanoma in China Keytruda is first I-O drug cleared for melanoma in China

    It’s not the first PD-1 inhibitor to get a green light in China, however, as Bristol-Myers Squibb pipped it to the post when it won approval for Opdivo ... Meanwhile, Hengrui Medicine also has an anti-PD-1 drug in registration trials, and there are

  • China’s BeiGene takes PD-1 antibody into pivotal trials China’s BeiGene takes PD-1 antibody into pivotal trials

    The PD-1/PD-L1 category has been transforming cancer treatment in Western markets, but so far just one of the five approved drugs have been launched in the big Chinese ... Along with BeiGene, Hengrui Medicine also has an anti-PD-1 drug in registration

  • Merck closes in on adjuvant melanoma indication for Keytruda Merck closes in on adjuvant melanoma indication for Keytruda

    Keytruda isn’t the first PD-1 inhibitor to show activity in this setting. ... Two positive trials make it likely adjuvant anti-PD-1 will become standard of adjuvant care for high-risk melanoma, rather than Yervoy which is associated with much more

  • MSD’s Keytruda wins bladder cancer indication in Japan MSD’s Keytruda wins bladder cancer indication in Japan

    MSD’ s Keytruda wins bladder cancer indication in Japan. Becomes first anti-PD1 approved in the country for previously treated UC. ... Baynes added: “We welcome the approval of Keytruda as the first anti-PD-1 therapy for these patients in Japan based

  • BMS’ Opdivo/Yervoy combination demonstrates OS benefit BMS’ Opdivo/Yervoy combination demonstrates OS benefit

    It found an overall survival benefit across programmed death ligand 1 (PD-L1) expression levels, which is how a patient responds to anti-PD-1/L1 antibodies. ... Renal cell carcinoma is the most common type of kidney cancer in adults, accounting for more

More from news
Approximately 3 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Gilead has been trying to diversify away from anti-viral therapies into oncology and Kite is a good fit with its CAR-T technology and a lead product in priority review ... Licence to develop and commercialise. GLS-010, anti-PD-1 antibody in phase I for

  • The new launch paradigm The new launch paradigm

    Thousands of patients worldwide are in clinical trials with anti-PD-1 or anti-PD-L1 drugs produced by several pharmaceutical companies prior to the expected arrival of this new exciting

  • Deal Watch July 2016 Deal Watch July 2016

    At the other end of the development spectrum Servier paid the same amount upfront for the rights to Sorrento's immuno-oncology product: STI-A1110, an anti-PD-1 mAb, presently ... Acquisition. 1, 530. AstraZeneca/ Leo Pharma. Tralokinumab (anti-IL-13) in

  • Deal Watch October 2015 Deal Watch October 2015

    Up to 3 anti-PD-1 based bispecific antibodies for oncology. Expansion of existing collaboration. ... Research collaboration, licence. 535. XOMA Corporation/ Novartis. Anti-transforming growth factor-beta (TGFb) antibody programme incl XOMA089 plus other

  • Pharma deals in September 2015 Pharma deals in September 2015

    Agenus will invest the proceeds in its growing pipeline of pre-clinical immuno-oncology treatments which include a series of PD-1 and CTLA-4 inhibitor programmes. ... Acquisition - company. 1, 230. Jiangsu Hengrui Medicine. Incyte. anti-PD-1, checkpoint

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics